Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study
Completed · Phase 2 · NCT05131477
Conditions: Eczema, Atopic Dermatitis
At a glance
- Research payments reported, 2025
- $6,250
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 390
About the trial
- Sponsor
- Kymab Limited (with Sanofi)
- Tested
- Amlitelimab (drug), Placebo (drug)
- Dates
- Started 2021-12-13; completion 2024-02-21
- Results posted
- Yes
This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 5-arm study to assess the effect of Anti-OX40L Monoclonal Antibody (KY1005) in adult participants with moderate to severe atopic dermatitis. The estimated duration is 28 days for screening and then up to approximately day 477 (last dose no later than day 337+140 days safety follow-up) for all patients unless enrolled into the Long-Term Extension (LTE) protocol (NCT05492578) at either Day 169 depending on responder status or no later than Day 365 due to loss of clinical response.
From ClinicalTrials.gov, last updated 2025-07-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Genzyme Corporation reported $6,250 in research payments for this study in 2025 (8 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $6,250
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.